Lantheus Alpha Therapy, LLC sold $357K of CATX
Lantheus Alpha Therapy, LLC sold 113,914 shares of Perspective Therapeutics, Inc. (CATX) at an average of $3.14 ($3.12–$3.14, $0.36M total) across 2 trades over 2026-08-31 to 2026-09-01.
How this was made
The 30-second read
Why it matters
The disclosed sale is a routine insider transaction with limited market impact.
Market read
Minor relevance; primarily of interest to shareholders monitoring insider activity.
What to watch
Potential upcoming clinical data releases could change relevance of insider activity.
Background
SEC Form 4 filing reports insider transactions for public companies.
Ticker impact
Form 4 disclosed Lantheus Alpha Therapy sold $357K of Perspective Therapeutics shares, reducing its stake to 11.56M shares.
little to no immediate price movement
The transaction size is modest relative to market cap and insider ownership remains high.
Market effects
None significant for the biotech sector.
No regional effect.
Limited to Perspective Therapeutics investors.
Counterpoint
Even small insider sales can signal concerns; watch for further disposals.
Key entities
- companyPerspective Therapeutics, Inc.
Biopharma company whose ticker is CATX.
- insiderLantheus Alpha Therapy, LLC
10% owner selling shares.